Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

A33 antigen displays persistent surface expression.

Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD.

Cancer Immunol Immunother. 2008 Jul;57(7):1017-27. doi: 10.1007/s00262-007-0433-x.

2.

Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium.

Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ.

Biochem Biophys Res Commun. 1997 Jul 30;236(3):682-6.

PMID:
9245713
3.

Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice.

Barendswaard EC, Scott AM, Divgi CR, Williams C Jr, Coplan K, Riedel E, Yao TJ, Gansow OA, Finn RD, Larson SM, Old LJ, Welt S.

Int J Oncol. 1998 Jan;12(1):45-53.

PMID:
9454885
4.
5.
6.

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.

Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW.

Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):469-74.

7.

Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium.

Moritz RL, Ritter G, Catimel B, Cohen LS, Welt S, Old LJ, Burgess AW, Nice EC, Simpson RJ.

J Chromatogr A. 1998 Mar 6;798(1-2):91-101.

PMID:
9542130
8.

In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.

Almqvist Y, Orlova A, Sjöström A, Jensen HJ, Lundqvist H, Sundin A, Tolmachev V.

Cancer Biother Radiopharm. 2005 Oct;20(5):514-23.

PMID:
16248767
9.

A33 antigen-deficient mice have defective colonic mucosal repair.

Pereira-Fantini PM, Judd LM, Kalantzis A, Peterson A, Ernst M, Heath JK, Giraud AS.

Inflamm Bowel Dis. 2010 Apr;16(4):604-12. doi: 10.1002/ibd.21114.

PMID:
19856415
10.

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.

Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF, et al.

J Clin Oncol. 1994 Aug;12(8):1561-71.

PMID:
8040668
11.

Transcriptional regulation of A33 antigen expression by gut-enriched Krüppel-like factor.

Mao Z, Song S, Zhu Y, Yi X, Zhang H, Shang Y, Tong T.

Oncogene. 2003 Jul 10;22(28):4434-43.

PMID:
12853980
12.

Cell-surface levels of human carcinoembryonic antigen are inversely correlated with colonocyte differentiation in colon carcinogenesis.

Ilantzis C, Jothy S, Alpert LC, Draber P, Stanners CP.

Lab Invest. 1997 May;76(5):703-16.

PMID:
9166289
13.

Glycoprotein A34, a novel target for antibody-based cancer immunotherapy.

Scanlan MJ, Ritter G, Yin BW, Williams C Jr, Cohen LS, Coplan KA, Fortunato SR, Frosina D, Lee SY, Murray AE, Chua R, Filonenko VV, Sato E, Old LJ, Jungbluth AA.

Cancer Immun. 2006 Jan 12;6:2.

14.

Human junction adhesion molecule regulates tight junction resealing in epithelia.

Liu Y, Nusrat A, Schnell FJ, Reaves TA, Walsh S, Pochet M, Parkos CA.

J Cell Sci. 2000 Jul;113 ( Pt 13):2363-74.

15.

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).

Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ, Welt S.

Cancer Res. 1997 Jun 1;57(11):2181-6.

16.

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Ackerman ME, Pawlowski D, Wittrup KD.

Mol Cancer Ther. 2008 Jul;7(7):2233-40. doi: 10.1158/1535-7163.MCT-08-0067.

17.

Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications.

Dauer LT, Boylan DC, Williamson MJ, St Germain J, Larson SM.

Health Phys. 2009 May;96(5):550-7. doi: 10.1097/01.HP.0000342831.26198.eb.

18.

Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy.

Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA, Kohleisen B.

Cancer Immunol Immunother. 2005 May;54(5):431-45. Epub 2004 Oct 16.

PMID:
15750830
19.

Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33.

Ji H, Moritz RL, Reid GE, Ritter G, Catimel B, Nice E, Heath JK, White SJ, Welt S, Old LJ, Burgess AW, Simpson RJ.

Electrophoresis. 1997 Mar-Apr;18(3-4):614-21.

PMID:
9150949
20.

Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis.

Wang H, Dong J, Shi P, Liu J, Zuo L, Li Y, Gong J, Gu L, Zhao J, Zhang L, Zhang W, Zhu W, Li N, Li J.

Immunology. 2015 Feb;144(2):254-62. doi: 10.1111/imm.12366.

Supplemental Content

Support Center